<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(11)</volume><submitter>Liao YJ</submitter><pubmed_abstract>Proton pump inhibitors (PPIs) are commonly prescribed medications. The existing data suggest that individuals at a high risk of fractures have been exposed to high doses of PPIs for prolonged durations. CYP2C19 plays a pivotal role in metabolism of PPIs and thereby influences their pharmacokinetic profile. Hence, we hypothesize that CYP2C19 genotypes may be associated with fragility fracture among PPIs users due to PPI exposure. This study aimed to investigate the association between CYP2C19 genotypes, bone mineral density (BMD), and osteoporotic fracture in a hospital-based population. This retrospective cohort study enrolled patients who were prescribed long-term PPIs at Taichung Veterans General Hospital using data extracted from the Taiwan Precision Medicine Initiative between January </pubmed_abstract><journal>Clinical and translational science</journal><pagination>2198-2208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10651637</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CYP2C19 genotypes and osteoporotic fractures in long-term users of proton pump inhibitors: A hospital-based study.</pubmed_title><pmcid>PMC10651637</pmcid><pubmed_authors>Hsu CS</pubmed_authors><pubmed_authors>Wu MF</pubmed_authors><pubmed_authors>Liao YJ</pubmed_authors><pubmed_authors>Chen YT</pubmed_authors><pubmed_authors>Hsu CY</pubmed_authors><pubmed_authors>Chen YM</pubmed_authors><pubmed_authors>Lin CH</pubmed_authors><pubmed_authors>Hsiao TH</pubmed_authors></additional><is_claimable>false</is_claimable><name>CYP2C19 genotypes and osteoporotic fractures in long-term users of proton pump inhibitors: A hospital-based study.</name><description>Proton pump inhibitors (PPIs) are commonly prescribed medications. The existing data suggest that individuals at a high risk of fractures have been exposed to high doses of PPIs for prolonged durations. CYP2C19 plays a pivotal role in metabolism of PPIs and thereby influences their pharmacokinetic profile. Hence, we hypothesize that CYP2C19 genotypes may be associated with fragility fracture among PPIs users due to PPI exposure. This study aimed to investigate the association between CYP2C19 genotypes, bone mineral density (BMD), and osteoporotic fracture in a hospital-based population. This retrospective cohort study enrolled patients who were prescribed long-term PPIs at Taichung Veterans General Hospital using data extracted from the Taiwan Precision Medicine Initiative between January </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Nov</publication><modification>2025-04-19T16:12:53.195Z</modification><creation>2025-04-19T16:12:53.195Z</creation></dates><accession>S-EPMC10651637</accession><cross_references><pubmed>37641483</pubmed><doi>10.1111/cts.13620</doi></cross_references></HashMap>